Powerful Combination for Win-Win Cooperation! SIGNDO Biotech and Hisense Medical have signed a strategic cooperation agreement
Recently, Jing Zhao, the founder and general manager of SIGNDO (Suzhou) Co., Ltd. (hereinafter referred to as "SIGNDO"), accompanied by Lizhi Zhang, the chief medical officer, and Ying Xu, the marketing director of SIGNDO, engaged in in-depth discussions and exchanges with Xueli Liu, the general manager of Qingdao Hisense Medical Equipment Co., Ltd. (hereinafter referred to as "Hisense Medical"), Yongjian Chen, the deputy general manager and general manager of the Endoscope Business Department of Hisense Medical, and Dongqiu Zhang, the deputy general manager of the Endoscope Business Department of Hisense Medical at the headquarters of Hisense Group Building. Subsequently, a strategic cooperation agreement was formally signed.
This time, through friendly consultations, SIGNDO and Hisense Medical aim to enhance the complementary advantages in their respective business domains. Not only will they strive for a seamless integration of drugs and equipment, but also conduct close cooperation in multiple aspects such as academic research and development, scientific research collaboration, product promotion, marketing strategies, and brand building. This is expected to drive the sustainable growth of both companies and boost their market competitiveness.
As a frontrunner in the domestic tumor-targeted fluorescent contrast agent industry, SIGNDO has strong capabilities in new drug research and development and clinical operation within the field of tumor-targeted fluorescent contrast agents. It has established a proprietary RT
TFC® research and development technology platform and developed several pipelines of tumor-targeted fluorescent contrast agents. Among them, DGPR1008 injection, the first independently developed pipeline product, is the first near-infrared tumor-targeted fluorescent contrast agent product approved by the Center for Drug Evaluation (CDE) in China, filling the gap in relevant domestic fields. At present, it has officially entered Phase II clinical trials. With good targeting and strong tumor-specific recognition ability, it has won praise from many doctors and has great influence in the field of tumor-targeted fluorescent contrast agents.
Hisense Medical, as one of the "Top 100 Chinese Medical Equipment Brands with Strongest Strength in 2024", has huge influence and development potential in the medical equipment field. Among them, the 4K fluorescent endoscope independently developed by Hisense Medical was approved by the National Medical Products Administration (NMPA) in May this year. With its advantages such as high-precision image registration, excellent fluorescence sensitivity and leading low image latency, this product demonstrates Hisense Medical's industry-leading position in core technologies.
The powerful combination of SIGNDO and Hisense Medical will give full play to the advantages and characteristics of all parties, continuously broaden the cooperation fields, improve the level of scientific research and development, and form a strategic cooperative relationship of mutual benefit and win-win results.
